249,488 Shares in Smith & Nephew plc (NYSE:SNN) Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. purchased a new stake in Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 249,488 shares of the medical equipment provider's stock, valued at approximately $6,132,000. Point72 Asset Management L.P. owned 0.06% of Smith & Nephew at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Principal Securities Inc. increased its stake in shares of Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 691 shares during the period. R Squared Ltd acquired a new stake in shares of Smith & Nephew in the fourth quarter valued at approximately $41,000. National Bank of Canada FI increased its stake in shares of Smith & Nephew by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 446 shares during the period. Hara Capital LLC increased its stake in shares of Smith & Nephew by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 1,957 shares during the period. Finally, Blue Trust Inc. increased its stake in shares of Smith & Nephew by 26.0% in the fourth quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock valued at $144,000 after purchasing an additional 1,213 shares during the period. Institutional investors and hedge funds own 25.64% of the company's stock.

Smith & Nephew Price Performance

NYSE SNN opened at $29.09 on Tuesday. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The firm has a market capitalization of $12.74 billion, a PE ratio of 13.47, a P/E/G ratio of 1.26 and a beta of 0.68. The company's 50 day simple moving average is $27.42 and its 200 day simple moving average is $26.29.

Smith & Nephew Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be paid a dividend of $0.447 per share. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, March 28th. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's dividend payout ratio (DPR) is currently 41.20%.

Analysts Set New Price Targets

SNN has been the topic of several analyst reports. UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group raised their price target on shares of Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. HSBC lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Hsbc Global Res lowered shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, StockNews.com upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat, Smith & Nephew presently has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.